|
Aplastic anemia: what have we learned from animal models and from the clinic.
|
Jun 2013
|
Semin Hematol
|
aplastic anemia
|
|
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndromes
|
Oct 2012
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
|
Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update
|
Oct 2012
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
|
Eltrombopag in aplastic anemia
|
Jan 2015
|
Semin Hematol
|
aplastic anemia
|
|
Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes
|
Oct 2012
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
|
Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab
|
Oct 2012
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
|
Detection of paroxysmal nocturnal hemoglobinuria (PNH) in bone marrow aspirates
|
Jan 2019
|
Semin Hematol
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Overview of myelodysplastic syndromes
|
Oct 2012
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
|
Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
|
Sep 2017
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
|
Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity
|
Sep 2017
|
Semin Hematol
|
myelodysplastic syndromes (MDS)
|
